Reveal Genomics and Ona Therapeutics have formed a strategic partnership to expedite the clinical development of the antibody-drug conjugate (ADC), ONA-255, tailored to improve the cancer treatment’s efficacy across a variety of solid tumour types.
ONA-255 is a first-in-class molecule aimed at a new ADC target found in numerous common solid tumours.
The collaboration is centred around Reveal Genomics鈥� chief scientific officer and co-founder Dr Aleix Prat, a drug development and precision oncology expert.
Dr Prat’s contributions include discovering the therapy drug target and generating key preclinical data with Ona and Dr Roger Gomis, crucial for the therapy鈥檚 clinical progression.
Reveal will carry out an extensive molecular analysis of blood samples and tumour from the therapy鈥檚 Phase I-II clinical trial.
The company will utilise technologies and computational algorithms to decode important molecular and genomic biomarkers, providing insights into the immune microenvironment, tumour biology and response mechanisms to the therapy.
The research aims to outline subject populations, pinpoint predictive biomarkers and enhance the therapy’s mechanism of action understanding.
Supporting this collaboration, Ona, in association with Reveal鈥檚 US subsidiary, has secured a grant from Centro para el Desarrollo Tecnol贸gico y la Innovaci贸n (CDTI) (the Spanish Ministry of Science and Innovation) and universities that encourages technological development and innovation.
This grant is provided by the Pland e Recuperaci贸n, Transformaci贸n y Resiliencia (the Recovery, Transformation and Resilience Plan), funded by the European Union’s NextGenerationEU.
Reveal Genomics CEO and co-founder Patricia Villagrasa stated: “Ona Therapeutics is at the forefront of developing next-generation cancer therapies.
鈥淭his collaboration marks a key milestone in combining advanced diagnostics with innovative treatments, reinforcing the strategic value of integrating biomarker science early in drug development.鈥�
In 2023, Biocytogen Pharmaceuticals and Ona agreed to develop ADCs for solid tumours.
